News & Media

Recent updates from Arcutis.

June 10, 2024

Arcutis Announces New Long-Term Data of Roflumilast Cream 0.15% for the Treatment of Mild to Moderate Atopic Dermatitis (AD) in Adults and Children Down to Age Six Presented at Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference

June 5, 2024

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 5, 2024

Arcutis Announces Multiple Abstracts, Including Oral Presentation, Accepted at the Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference

June 3, 2024

Arcutis to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

May 14, 2024

Arcutis Announces First Quarter 2024 Financial Results and Provides Business Update

May 13, 2024

Expert Panel Review Further Validates Use of ZORYVE® (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic Dermatology

May 3, 2024

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 29, 2024

Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024

April 10, 2024

Arcutis Appoints David Topper as Chief Financial Officer

April 5, 2024

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 28, 2024

Arcutis to Present at the 23rd Annual Needham Virtual Healthcare Conference

March 11, 2024

Arcutis Promotes Todd Tucker to Chief Human Resources Officer

Media Resources

Corporate Fact Sheet

Uncovering Psoriasis

Journal of the American Medical Association Roflumilast Cream 0.3% Result

Media Contact

Amanda Sheldon

805.418.5006
media@arcutis.com

Meaningful innovation at a glance.

Download our corporate fact sheet.

Download